journal article·2025-12Open access

Targeted Enrichment of Engineered Bacteria on Triple‐Negative Breast Cancer Turns Immunologically Cold Tumors Hot

Xuanxiang Zhai, Xiaoyi Shi, Xiao Liu, Xiaotong Gu, Wenting Li, Xiangjun Chen, Wei Hong

Advanced Science· Volume 12· Issue 47

Abstract

Abstract Tumor immunotherapy has garnered significant attention, however, several notable challenges remain to be addressed, including: 1) enhancing active targeting, 2) effectively shielding immune checkpoints, and 3) inducing the transformation of “cold” tumor into “hot”. In this study, an “all‐in‐one” extracellular anaerobic bacterial nanocomposite system is constructed. Escherichia coli Nissle 1917 (EcN) is enveloped with polydopamine via self‐polymerization ( PDA EcN), subsequently conjugated with a chitosan oligosaccharide (COS) nanoparticle immunostimulant backpack, denoted as PDA EcN/COS. The PDA coating is capable of concealing EcN polysaccharides, masking the immunogenic bacterial surface antigens, and inducing a mild photothermal therapy (PTT) effect. Moreover, PDA EcN/COS exhibits targeted accumulation in hypoxic regions of solid tumors and demonstrates pronounced enrichment on tumor cell surfaces, attributed to the bacterial hypoxic region targeting ability and adhesive properties of PDA, physically obstructing the immune checkpoint. Simultaneously, both EcN and COS markedly enhanced the transformation of M2 macrophages into the M1 phenotype, whereas mild PTT‐induced immunogenic cell death (ICD) further mitigated the immunosuppressive nature of the hypoxic tumor microenvironments (TMEs). This integrated therapeutic approach eradicated tumors without eliciting metastasis or discernible side effects following a single injection and laser irradiation in a murine 4T1 cancer model. Ultimately, the immunostimulatory capacity of PDA EcN/COS is considered to hold significant potential for developing novel and efficacious therapies for immunologically “cold” triple‐negative breast cancer (TNBC).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy Shandong New Drug Loading & Release Technology and Preparation Engineering Laboratory Binzhou Medical University 346 Guanhai Road Yantai 264003 P. R. China

Funding

Natural Science Foundation of Shandong Province · Taishan Scholar Foundation of Shandong Province

References (42)

Show source-provided references
1. 10.1146/annurev-pathol-042420-09323810.1146/annurev-pathol-042420-093238 ↗
2. 10.3390/pharmaceutics502035310.3390/pharmaceutics5020353 ↗
3. 10.1002/advs.20150005310.1002/advs.201500053 ↗
4. 10.1016/j.jconrel.2020.07.00310.1016/j.jconrel.2020.07.003 ↗
5. 10.1126/science.359.6382.134410.1126/science.359.6382.1344 ↗
6. 10.1002/anie.20210205910.1002/anie.202102059 ↗
7. 10.1073/pnas.19246109910.1073/pnas.192461099 ↗
8. 10.1007/s10555-021-09972-410.1007/s10555-021-09972-4 ↗
9. 10.1002/adhm.20180109910.1002/adhm.201801099 ↗
10. 10.1038/nature1398810.1038/nature13988 ↗
11. 10.1001/jamaoncol.2018.392310.1001/jamaoncol.2018.3923 ↗
12. 10.1016/j.semcancer.2019.12.01910.1016/j.semcancer.2019.12.019 ↗
13. 10.1084/jem.2005091510.1084/jem.20050915 ↗
14. 10.1038/nri.2016.15310.1038/nri.2016.153 ↗
15. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
16. 10.1021/acsami.2c0725410.1021/acsami.2c07254 ↗
17. 10.1039/D1TB00397F10.1039/D1TB00397F ↗
18. 10.1016/j.biomaterials.2022.12181510.1016/j.biomaterials.2022.121815 ↗
19. 10.1038/s41467-018-03473-910.1038/s41467-018-03473-9 ↗
20. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
21. 10.1021/acsami.1c1113810.1021/acsami.1c11138 ↗
22. 10.1002/advs.20170080510.1002/advs.201700805 ↗
23. 10.1038/s41577-020-0406-210.1038/s41577-020-0406-2 ↗
24. 10.1158/0008-5472.CAN-19-092810.1158/0008-5472.CAN-19-0928 ↗
25. 10.1016/j.addr.2022.11413610.1016/j.addr.2022.114136 ↗
26. 10.1038/ni.193710.1038/ni.1937 ↗
27. 10.1016/j.jconrel.2021.11.02810.1016/j.jconrel.2021.11.028 ↗
28. 10.1002/advs.20210383610.1002/advs.202103836 ↗
29. 10.1021/acsnano.1c0670710.1021/acsnano.1c06707 ↗
30. 10.1080/20013078.2020.180644410.1080/20013078.2020.1806444 ↗
31. 10.3389/fimmu.2023.114046310.3389/fimmu.2023.1140463 ↗
32. 10.1002/advs.20200357210.1002/advs.202003572 ↗
33. 10.1016/j.actbio.2021.06.03010.1016/j.actbio.2021.06.030 ↗
34. 10.1016/j.cell.2022.02.02710.1016/j.cell.2022.02.027 ↗
35. 10.1002/advs.20230167910.1002/advs.202301679 ↗
36. 10.1002/adma.20230538410.1002/adma.202305384 ↗
37. 10.1039/D3MH00249G10.1039/D3MH00249G ↗
38. 10.1021/acsnano.8b0223510.1021/acsnano.8b02235 ↗
39. 10.1021/acsami.2c1824410.1021/acsami.2c18244 ↗
40. 10.1002/advs.20230405310.1002/advs.202304053 ↗
41. 10.1016/j.intimp.2014.09.00710.1016/j.intimp.2014.09.007 ↗
42. 10.3892/ol.2014.211510.3892/ol.2014.2115 ↗